Total Payments
$1,563
2024 Payments
$357.04
Companies
24
Transactions
48
Medicare Patients
7,728
Medicare Billing
$2.8M
Payment Breakdown by Category
Food & Beverage$1,243 (79.6%)
Education$319.61 (20.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,243 | 43 | 79.6% |
| Education | $319.61 | 5 | 20.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $208.54 | 2 | $0 (2018) |
| Abbott Laboratories | $149.62 | 1 | $0 (2022) |
| Lilly USA, LLC | $135.62 | 2 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $133.27 | 7 | $0 (2024) |
| Astellas Pharma US Inc | $95.00 | 1 | $0 (2020) |
| Janssen Biotech, Inc. | $92.51 | 4 | $0 (2023) |
| Celgene Corporation | $92.04 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $85.12 | 4 | $0 (2024) |
| Incyte Corporation | $83.99 | 1 | $0 (2024) |
| Merck Sharp & Dohme LLC | $61.56 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $357.04 | 16 | Incyte Corporation ($83.99) |
| 2023 | $164.03 | 8 | Janssen Biotech, Inc. ($71.97) |
| 2022 | $205.61 | 4 | Abbott Laboratories ($149.62) |
| 2021 | $50.99 | 2 | Medtronic, Inc. ($38.87) |
| 2020 | $109.87 | 2 | Astellas Pharma US Inc ($95.00) |
| 2019 | $61.95 | 3 | Foundation Medicine, Inc. ($26.92) |
| 2018 | $412.17 | 8 | AstraZeneca Pharmaceuticals LP ($124.97) |
| 2017 | $201.28 | 5 | AstraZeneca Pharmaceuticals LP ($83.57) |
All Payment Transactions
48 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/11/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $24.47 | General |
| Category: Hematology | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $83.99 | General |
| 09/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $16.29 | General |
| Category: Oncology | ||||||
| 09/11/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $16.97 | General |
| Category: Hematology | ||||||
| 07/31/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.43 | General |
| Category: Hematology | ||||||
| 07/09/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Oncology | ||||||
| 07/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $18.69 | General |
| Category: Oncology | ||||||
| 05/22/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: BioOncology | ||||||
| 05/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.59 | General |
| Category: Oncology | ||||||
| 04/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $17.93 | General |
| Category: Oncology | ||||||
| 04/24/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.92 | General |
| Category: Hematology | ||||||
| 03/28/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 03/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $15.39 | General |
| Category: Oncology | ||||||
| 11/16/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.25 | General |
| Category: Hematology | ||||||
| 10/07/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: Oncology | ||||||
| 08/23/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: Oncology | ||||||
| 05/12/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $12.96 | General |
| Category: Oncology | ||||||
| 04/25/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: Oncology | ||||||
| 03/31/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: Oncology | ||||||
| 10/18/2022 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 35 | 1,746 | 35,037 | $2.4M | $615,519 |
| 2022 | 41 | 1,950 | 41,334 | $2.8M | $752,301 |
| 2021 | 34 | 2,203 | 27,761 | $2.4M | $833,987 |
| 2020 | 29 | 1,829 | 8,565 | $1.6M | $578,482 |
Total Patients
7,728
Total Services
112,697
Medicare Billing
$2.8M
Procedure Codes
139
All Medicare Procedures & Services
139 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 9,400 | $1.5M | $407,031 | 27.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 285 | 796 | $310,440 | $67,437 | 21.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 2,700 | $172,800 | $49,606 | 28.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 61 | 165 | $69,465 | $14,521 | 20.9% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 13 | 13,500 | $54,000 | $11,861 | 22.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 125 | 163 | $45,151 | $9,641 | 21.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 64 | 64 | $43,072 | $8,743 | 20.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 282 | 915 | $26,535 | $6,929 | 26.1% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 15 | 3,640 | $21,840 | $4,974 | 22.8% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 15 | 63 | $13,230 | $4,528 | 34.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 33 | $18,150 | $4,105 | 22.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 89 | 270 | $10,530 | $2,757 | 26.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $11,900 | $2,607 | 21.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 24 | 58 | $11,890 | $2,501 | 21.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 163 | 286 | $2,574 | $2,380 | 92.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 43 | 194 | $12,804 | $2,056 | 16.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 31 | 102 | $10,506 | $2,015 | 19.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 22 | $6,776 | $1,967 | 29.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 32 | 44 | $9,152 | $1,861 | 20.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 49 | 125 | $8,375 | $1,148 | 13.7% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 12 | 27 | $4,779 | $928.71 | 19.4% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 15 | 40 | $4,200 | $908.40 | 21.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 14 | 56 | $3,976 | $890.36 | 22.4% |
| 85045 | Red blood count, automated test | Office | 2023 | 118 | 217 | $2,604 | $844.56 | 32.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 14 | 38 | $6,232 | $714.15 | 11.5% |
About Dr. Dushyant Verma, MD
Dr. Dushyant Verma, MD is a Internal Medicine healthcare provider based in Springfield, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164477014.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dushyant Verma, MD has received a total of $1,563 in payments from pharmaceutical and medical device companies, with $357.04 received in 2024. These payments were reported across 48 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($1,243).
As a Medicare-enrolled provider, Verma has provided services to 7,728 Medicare beneficiaries, totaling 112,697 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 139 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Springfield, MO
- Active Since 05/22/2006
- Last Updated 12/03/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1164477014
Products in Payments
- AMPLATZER AMULET (Device) $149.62
- CALQUENCE (Drug) $124.97
- DARZALEX (Biological) $92.51
- LYNPARZA (Drug) $83.57
- OPDUALAG (Drug) $68.30
- REBLOZYL (Biological) $67.57
- KEYTRUDA (Biological) $61.56
- ADCETRIS (Biological) $45.47
- FOUNDATIONONE (Device) $43.59
- OPDIVO (Biological) $43.30
- Optune (Device) $41.25
- KYPHON Balloon Kyphoplasty (Device) $38.87
- Erleada (Drug) $37.14
- Alecensa (Biological) $24.89
- KISQALI (Drug) $24.89
- Pomalyst (Drug) $24.47
- VERZENIO (Drug) $23.56
- TECENTRIQ (Biological) $21.86
- PLUVICTO (Drug) $21.71
- MEKINIST (Drug) $21.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Springfield
Dr. Steven Gradney, M.d, M.D
Internal Medicine — Payments: $568,658
Internal Medicine $568,658
Dr. James Bonucchi, Do, DO
Internal Medicine — Payments: $304,681
Internal Medicine $304,681
John Flack, Md, Mph, MD, MPH
Internal Medicine — Payments: $125,897
Internal Medicine $125,897
Dr. Sudeshna Banerjee, Md, MD
Internal Medicine — Payments: $62,767
Internal Medicine $62,767
Dr. Paul Madaj, M.d, M.D
Internal Medicine — Payments: $58,030
Internal Medicine $58,030
Dr. Indrajeet Mahata, M.d, M.D
Internal Medicine — Payments: $47,372
Internal Medicine $47,372